Ranitidine suppresses aluminium absorption in man.
1. Intragastric pH monitoring was performed before and after the single-blind administration of ranitidine or placebo (saline) in eight healthy subjects and four patients with end-stage renal disease who were on regular haemodialysis. 2. The subjects were studied on two occasions and were given aluminum hydroxide (1185 mg) orally 90 min after the administration of ranitidine or saline. 3. Plasma aluminum concentrations and, in normal men, urinary excretion of aluminum were monitored before and after the oral aluminum load. 4. Intragastric pH increased significantly with ranitidine but not with placebo (P less than 0.001). Urinary aluminum excretion increased significantly after the administration of aluminum hydroxide during the placebo phase (P less than 0.001) but not during the ranitidine phase. Plasma aluminium concentrations were higher in the patients with renal failure than in the normal subjects (P less than 0.05), but were unchanged in both groups after the oral aluminium load. 5. This study shows that gastric pH is an important factor in the modulation of aluminum absorption in man, and indicates that reducing gastric acid secretion with ranitidine may reduce the toxicity of orally administered aluminium compounds.
Rodger
R S
RS
Renal Unit, Stobhill General Hospital, Glasgow, U.K.
Muralikrishna
G S
GS
Halls
D J
DJ
Henderson
J B
JB
Forrest
J A
JA
Macdougall
A I
AI
Fell
G S
GS
D000328:Adult; D000535:Aluminum / Q000378:metabolism*; D000536:Aluminum Hydroxide / Q000494:pharmacology; D003864:Depression, Chemical; D005744:Gastric Acid / Q000378:metabolism*; D005745:Gastric Acidity Determination; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects*; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy; D008297:Male; D011899:Ranitidine / Q000494:pharmacology*; D006435:Renal Dialysis; D016037:Single-Blind Method
D000536:Aluminum Hydroxide; D011899:Ranitidine; D000535:Aluminum